Baxter and Mayo Clinic announce collaboration
Baxter International Inc., a global innovator in renal care, and Mayo Clinic Tuesday announced a new collaboration to develop a renal care center of excellence in the U.S.
The center will serve patients across the continuum of renal care -- from chronic kidney disease management through transplant -- and drive better patient outcomes.
The center is being established at the Mayo Clinic Dialysis Center at the campus in Jacksonville, Florida, where Mayo Clinic's recognized excellence in care will be integrated with Baxter Renal Care Services' proven clinical service model and CKD management program. The Mayo Clinic Dialysis Center in Jacksonville provides state-of-the-art dialysis services in a homelike facility. The collaboration will also allow for the trial of potentially new, codeveloped products and services.
"The collaboration between Mayo Clinic and Baxter combines the best of our clinical, research and innovation expertise, and is rooted in the shared goal to improve the way we care for patients with serious and complex illnesses," said Dr. Gianrico Farrugia, CEO of Mayo Clinic in Florida and president-elect of Mayo Clinic. "We are excited to establish this new renal care center of excellence with Baxter."
"We firmly believe there is a path to better care for kidney patients, which starts by managing the disease before dialysis is required and through simpler, more effective innovations," says Laura Angelini, general manager, Baxter's Renal Care business. "Our collaboration with Mayo Clinic will allow us to go even further in helping to establish transformative care."
The dialysis clinic collaboration is the first launched initiative from the Baxter and Mayo Clinic five-year agreement announced in 2017, allowing the two health care leaders to bring together their respective clinical and development expertise. The primary emphasis of the broader agreement focuses on new research and development projects to advance innovation across different therapeutic areas where there are high unmet patient needs, such as renal disease. The initial agreement is for a five-year period, with a five-year renewal option.